The continuous increase in elderly and oldestold population, and subsequent rise in prevalence of chronic neurological diseases like Alzheimer's disease (AD) and Parkinson's disease (PD), are a major challenge for healthcare systems. These two conditions are the most prevalent neurodegenerative diseases in older persons and physicians should engage treatment for these patients. In this field, Randomized Clinical Trials (RCTs) specifically focused on elderly populations are still lacking. The aim of this study was to identify RCTs conducted among AD and PD and to examine the difference between mean age of enrollment and incidence of these two neurodegenerative diseases. We found that the scenario is different between PD and AD. In particular, the enrollment for PD trials seems to include younger persons than AD, although the incidence of both diseases is similar and highest after 80 years old. The consequence of these results could influence conclusive guidelines of treatment in older parkinsonian patients.
Multimorbidity, clinical complexity, age-related changes in body composition and physiology and polypharmacy generally prevent the inclusion in such studies (1) .
The reasons are well-known. Elderly patients have more disability and co-morbidities than younger persons and the age-related changes in body composition and physiology lead to a higher rate and intensity of adverse events.
Many neurological diseases are highly prevalent in older persons (2,3). Alzheimer's disease (AD) is the sixth leading and fastest growing cause of death worldwide, and the only one of the top 10 causes with no means of prevention or cure (2) . Most people only live for 8 to 10 years after a diagnosis of AD, and between 5% and 10% of those with AD are in their 30s, 40s, and 50s when diagnosed (2). Parkinson's disease (PD) is an age-related neurodegenerative disorder that affects as many as 1-2% of persons aged 60 years and older (3) . With the aging of the population, the prevalence of PD is expected to increase dramatically in the future (4) . PD is an age-related disease, rare before 50 years of age and with a prevalence of up to 4% in the highest age groups. Some studies report a higher prevalence of PD in men than in women, although other studies found no significant differences between sexes (4). Interestingly, signs of parkinsonism are frequently found on neurologic examination in older people without an overt PD (5) . © 1996-2016 These signs are often regarded as benign (5) . However, data regarding their prevalence and relation to disability in older persons showed that they were associated with increased risk of falling (6) and with higher levels of disability in performing both physical and instrumental activities of daily living (7).
Changes in cognition and locomotion emerge simultaneously in elderly persons at the first neurological/ geriatric visit and this could be a sign of mixed neurodegenerative diseases or AD with parkinsonism or PD with cognitive impairment (Figure 1 ) (8).
Recently, it has been proposed the definition of "motoric cognitive risk" syndrome for a condition with cognitive impairment and reduced walking speed. This is an isolated pre-dementia condition, that could be a marker of a specific disease where cognitive and motor systems are compromised in older persons (9). This condition, such as other mixed diseases (10), could be related to an alteration in both dopamine and acetylcholine neurotransmitters, which are involved in PD and AD, respectively ( Figure 1 ). In fact, treatment for PD and AD include drugs that act on dopamine or acetylcholine, and their balance is the main core of the motor and cognitive symptoms for both these neurodegenerative diseases ( Figure 2 ) (11). A stable clinical condition in PD can be obtained only balancing motor and psychotics symptoms through a careful dopamine pharmacological dose adjustment. In AD the most effective pharmacological treatment is administration of antipsychotics, especially atypical, that do not increase extrapyramidal symptoms, leading to a reduction of falls and mobility-disability.
Thus, the aim of this paper was to analyze the appropriateness of the RCTs conducted among neurodegenerative diseases in older persons, in terms of comparison between mean age of enrollment and mean age of incidence of these diseases. Figure 3 shows the prevalence of the PD and AD across decades of persons older than 65 years old. The prevalence for both diseases increases with aging with a peak after 85 years old. We calculated the mean age of RTCs in AD and PD across the most recent metaanalyses and systematic reviews (Figure 4 ). The mean age of RTCs for AD is 75 years old, while mean age for PD is 67.5 years old. Table 1 shows the mean age, numbers, gender and main outcomes of subjects enrolled in the RCTs carried out in AD for cognitive, behavioral and psychological symptoms of dementia (BPSD). Overall, the mean age of these studies is in line with the incident and prevalent mean age of this disease, as shown in Figure 4 . The sample size of these RCTs also reached a sufficient number of participants avoiding population bias. Namely, the mean age of enrolled subjects was greater than 70 years old and even higher (>80 years old) for studies addressing behavioral and sleep disorders.
RESULTS OF RANDOMIZED CONTROLLED TRIALS INCLUDED IN THE COCHRANE REVIEWS AND OTHER SYSTEMATIC REVIEWS AND META-ANALYSES FOR ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE

RCT in AD
RCT in AD: Cognitive symptoms
Thirteen randomized, double blind, placebocontrolled trials for evaluation of cognitive symptoms in They demonstrated that administration of donepezil, galantamine or rivastigmine at the recommended dose to people with mild, moderate or severe Alzheimertype dementia for a period of 6 months or 1 year was associated with improvement in cognitive function. The variation in the 70-point Alzheimer's disease assessment scale-cognition (ADAS-Cog) was on average -2.7 points (95% CI -3.0. to -2.3.) (12).
RCT in AD: BPSD
All RCTs were identified in the most recent literature and included in previous meta-analyses and systematic reviews. Overall, they showed that cholinesterase inhibitors (ChEIs) and atypical antipsychotics improved Neuropsychiatric Inventory (NPI) total scores (ChEIs: standardized mean difference (SMD) −0.1.2; 95% CI −0.2.3 to −0.0.2; atypical antipsychotics: SMD −0.2.1; 95% CI −0.2.9 to −0.1.2). However, other commonly used drugs like antidepressants (95% CI −0.3.5 to 0.3.7) and memantine (95% CI −0.2.7 to 0.0.3) did not. ChEIs and atypical antipsychotics increased the risk of dropouts due to adverse events (ChEIs: risk ratio (RR) 1.6.4; 95% CI 1.1.2 to 2.4.2; atypical antipsychotics: RR 2.2.4; 95% CI 1.5.3 to 3.2.6) and on incidence of adverse events (ChEIs: RR 1.0.8; 95% CI 1.0.1 to 1.1.7; atypical antipsychotics: RR 1.1.7; 95% CI 1.0.5 to 1.3.1). For typical antipsychotics, no study was included for testing this specific outcome. Therefore, as suggested by many authors, ChEIs and atypical antipsychotics could improve neuropsychiatric symptoms in AD patients, but adverse events should be considered when these drugs are prescribed, especially in very old patients (27) .
RCT in AD: Sleep disorders
A recent Cochrane Database systematic review reported that there is a lack of evidence to help guided drug treatment of sleep problems in AD (28) . Namely, they found that no RCTs have been performed despite the large number of drugs that are widely prescribed for sleep problems in AD, like the benzodiazepines and non-benzodiazepine hypnotics. As such, there is still a considerable uncertainty about the balance of benefits and risks associated with these common treatments. Melatonin was not found as beneficial to AD patients with moderate to severe dementia and sleep problems. There is some evidence to support the use of a low dose (50 mg) of trazodone, although larger trials would be needed to reach a more definitive conclusion and focus risks and benefits. No evidence of any effect of mirtazapine on sleep in patients with mild to moderate dementia due to AD was found. As such, McCleery et al. concluded that this is an area with a high need for pragmatic trials, particularly on those drugs that are in common clinical use for sleep problems in AD (28) . Systematic assessment of adverse effects is essential in clinical trials, particularly when including very old patients with a high risk of negative outcomes. Table 2 shows the mean age, number, gender and main outcomes of participants to the RCTs realized in PD for both motor and non-motor symptoms. Contrary to AD, the mean age of RCT testing the efficacy of several drugs for motor symptoms in PD does not match the real age of onset of this disease, as showed in Figure 3 and Figure 4 . In fact, the mean age of participants in these studies is nearly 60 years old, while the peak of incidence of the disease appears at least two decades after. Moreover, there are very few studies testing the effects of these drugs on sleep disorders. 
RCT in PD
RCT in PD: Motor symptoms
RCTs showed that levodopa is the most important drug for treatment of motor symptoms in PD. However, compared to placebo, adjuvant therapy, with dopamine agonist, reduces off-time, levodopa dose, and improves unified Parkinson's disease rating scale (UPDRS) scores in PD patients who develop motor complications on levodopa therapy. It is well established that treatment with levodopa is at the expense of increased dyskinesia and many other side-effects. Many authors showed that the risk of motor complications with levodopa therapy significantly increased when the dosage is higher than 400 mg/die (44).
Indirect comparisons suggest that dopamine agonist therapy may be more effective than catechol-Omethyltransferase inhibitors (COMTI) and monoamine oxidase type B inhibitors (MAOBI) therapy, which have comparable efficacy. However, as indirect comparisons should be interpreted with caution, direct head-to-head randomized trials assessing the impact of these different drug classes on overall patient-rated quality of life are needed (30) . Adequate clinical trials including more people at advanced age, as showed by incidence age of this disease, should be carried out. They should not consider a class-effect, but select singular drugs, especially the dopamine agonist, where the reported adverse effects, such as impulse control disorders (ICDs), are different for each specific drug (45).
RCT in PD: Non-motor symptoms
RCTs showed that cholinesterase inhibitors and memantine slightly improve global impression scale in PD; however, only cholinesterase inhibitors enhance cognitive function. Besides, all the drugs have good safety outcomes (31) . The limited number of trials precluded the generalization of these outcomes, especially in very old PD patients (42) .
Clozapine and quetiapine are the only two drugs whose use can be recommended in PD with psychotic symptoms (43) . These two drugs are quite different each other, but dosage and side-effects are well known even in older persons (43) and this allows a safe use and prescription.
DISCUSSION
We found that the scenario is different between PD and AD. In particular, the enrollment for PD trials seems to include younger persons than AD, although the incidence of both diseases is similar and highest after 80 years old.
PD generally affects mobility, although in the last decade non-motor manifestations and the bradikinetic form with increased falls have been recognized as relevant symptoms affecting mobility-disability and quality of life. Classically, the disease is diagnosed after the appearance of typical motor symptoms and nonmotors symptoms are usually not recognized at the moment of the diagnosis. However, many older persons show minor neurological signs, including those indicative of parkinsonism, that are considered age-related, and a standardized evaluation for the diagnosis of PD is not made, even in very old persons. The diagnosis of PD could be hence under-estimated in older persons. This may be the main limitation of enrollment of older PD patients in RTCs. Multimorbidity is the main factor limiting the inclusion of older persons in RTCs, but in most cases a missed diagnosis of PD is the reason for excluding very old patients in such studies.
In PD, levodopa remains the drug of reference, although, when the dosage is increased to more than 400 mg/day, the onset of typical side-effect should be taken into account after few years (44) . Therefore, treatment with levodopa should be avoided or delayed in younger subjects, preferring other non-ergot dopamineagonist with a more favorable pharmacological profile as first-line therapy. The effectiveness of AchEi on cognitive performance in PD is well-established, while only two For AD the level of evidence is different from PD. In fact, the analyzed RTCs have shown an higher mean age of enrollment compared to PD, especially when psychiatric symptoms of AD were studied. In this case the most important open question is the precocity of the diagnosis, for preventing the deposition of the amyloid, but in this direction the neuroimaging techniques are promising to establish an early diagnosis, even in older persons (46) . Actually, only standard-dose treatment with donepezil, galantamine or rivastigmine produced improvements in cognitive function in AD. Psychotics symptoms could be treated with atypical antipsychotics instead of typical ones, although cardiovascular sideeffects should be carefully evaluated.
The problem of missing RCTs in older persons is now well known in many chronic diseases, as well emphasized by Cherubini et al. (47) , evaluating RTCs for heart failure. These authors showed that among 251 trials investigating treatments for heart failure, 64 (25.5%) excluded patients by an arbitrary upper age limit. Such exclusion was significantly more common in trials conducted in the European Union than in the United States (32.3% vs 16.2%) and in drug trials sponsored by public institutions compared those by private entities (35.6% vs 13.9%). They also found that 109 trials (43.4.%) on heart failure had one or more poorly justified exclusion criteria that could limit the inclusion of older individuals.
This observation has now allowed to create, at least in Europe, a network for studying the lack of evidence in older persons, focused on the most prevalent chronic diseases, with the aim of avoiding off-labels use of many drugs commonly prescribed in clinical practice. One example is the PREDICT consortium, established by the European Community, and aimed at identifying, addressing and resolving the issues related to the exclusion of older people from RCTs using full range of relevant scientific and clinical disciplines (48) .
In conclusions, a selection or population bias exists for RTCs in PD, as expected, since they generally enroll younger patients in comparison of the mean age of incidence of the disease. This could not permit to have a conclusive guideline for caring older persons with PD.
For AD the situation is different, because mean age of enrollment is almost a decade higher than PD although, the peak of incidence in age is similar among these two diseases.
To avoid biases and to improve usefulness of RCT results in clinical practice, a multidisciplinary approach, involving also geriatricians, is recommended for establishing appropriate inclusion criteria and promoting enrolment of older persons. © 1996-2016 
